Edit Reading

Back to List

Basic Information

Title

Please enter a title.

URL

Please enter a valid URL.

Date

カテゴリID

画像ファイル名

統計情報

単語数: 155語

読了回数: 0回

作成日: 2023/01/07 08:15

更新日: 2025/12/09 09:31

本文

The US Food and Drug Administration has approved a new drug for Alzheimer&#039;s disease jointly developed by Japanese pharmaceutical firm Eisai and US partner Biogen.
                
The FDA announced on Friday that it had given the green light to lecanemab after confirming the drug&#039;s efficacy.
                
Researchers evaluated the drug in a study of about 850 patients. The results confirm a &quot;reduction of amyloid beta plaque, a marker of Alzheimer&#039;s disease.&quot;
                
Lecanemab becomes the second US-approved Alzheimer&#039;s drug targeting amyloid beta.
                
The FDA says, &quot;These medications represent an important advancement in the ongoing fight to effectively treat Alzheimer&#039;s disease.&quot;
                
Lecanemab is believed to slow the advancement of the disease by preventing the destruction of brain cells.
                
The FDA says the drug should be initiated in Alzheimer&#039;s patients with mild cognitive impairment or mild dementia, adding that brain cells cannot be regenerated once damaged.
                
Approval was given under a fast-track process for drugs designed to treat serious conditions.

本文を入力してください。

メモ

メモ・感想

キャンセル

Edit Reading

Basic Information

統計情報

本文

メモ

Send Report